Cara Therapeutics, Inc.

TVRD

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TVRD
CIK0001346830
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT, 06902
Website caratherapeutics.com
Phone203-406-3700
CEOChristopher Posner
Employees80

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$7.57 million
Pre-Tax Income$-45.48 million
Net Income$-45.08 million
Net Income to Common$-45.08 million
EPS$-29.58
View All
Balance Sheet
Cash$34.22 million
Assets$38.95 million
Liabilities$47.02 million
Common Equity$-8.07 million
Liabilities & Equity$38.95 million
View All
Cash Flow Statement
Calculations
NOPAT$-21.77 million
EBITDA$-31.73 million
Price to EarningsN/A
Price to BookN/A
ROE-414.88%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. “The effects of the stock marke

Article Link

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

HOUSTON, May 27, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical t

Article Link

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

HOUSTON, May 20, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, N

Article Link

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

HOUSTON, May 13, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.

Article Link

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

HOUSTON, May 06, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco.

Article Link